Stock A263050 EUTILEX.CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Eutilex.Co.,Ltd Share Price

Equities

A263050

KR7263050007

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 19/05/2024 BST 		5-day change 1st Jan Change
2,240 KRW -0.88% Intraday chart for Eutilex.Co.,Ltd +0.22% -33.73%
03-21 Eutilex.Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Eutilex.Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Financials

Sales 2022 216M 159K 12.46M Sales 2023 132M 96.77K 7.61M Capitalization 124B 91.32M 7.18B
Net income 2022 -33.43B -24.57M -1.93B Net income 2023 -27.72B -20.37M -1.6B EV / Sales 2022 857 x
Net cash position 2022 59.24B 43.54M 3.42B Net cash position 2023 33.16B 24.37M 1.92B EV / Sales 2023 692 x
P/E ratio 2022
-5.84 x
P/E ratio 2023
-4.48 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 70.41%
More Fundamentals * Assessed data

Chart Eutilex.Co.,Ltd

Dynamic Chart

Latest news about Eutilex.Co.,Ltd

Eutilex.Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Eutilex.Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Eutilex.Co.,Ltd(KOSDAQ:A263050) dropped from S&P Global BMI Index CI
Eutilex.Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Eutilex.Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Eutilex.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Eutilex.Co.,Ltd. announced that it has received KRW 22.5003376 billion in funding CI
Eutilex.Co.,Ltd. announced that it expects to receive KRW 22.5003376 billion in funding CI
Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA CI
Eutilex.Co.,Ltd. announced that it has received KRW 19.9998552 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd., Asset One CI
Eutilex.Co.,Ltd. announced that it expects to receive KRW 19.9998552 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd., Asset One CI
Eutilex Co.,Ltd. announced that it has received KRW 29 billion in funding CI
Eutilex Co.,Ltd. announced that it expects to receive KRW 29 billion in funding CI
CDMO business GenScript ProBio and Eutilex Co., Ltd. Enter into Exclusive Strategic Collaboration on Plasmid and Virus Process Development and Manufacturing for Car-T Programs CI
Eutilex Co.,Ltd.(KOSDAQ:A263050) added to S&P Global BMI Index CI
More news

Quotes and Performance

1 day-0.88%
1 week+0.22%
Current month+1.36%
1 month+2.52%
3 months-15.63%
6 months-16.88%
Current year-33.73%
More quotes

Highs and lows

1 week
2 230.00
Extreme 2230
2 305.00
1 month
2 175.00
Extreme 2175
2 305.00
Current year
2 095.00
Extreme 2095
3 690.00
1 year
2 095.00
Extreme 2095
5 420.00
3 years
2 095.00
Extreme 2095
25 600.00
5 years
2 095.00
Extreme 2095
41 133.33
10 years
2 095.00
Extreme 2095
48 166.67
More quotes

Managers and Directors - Eutilex.Co.,Ltd

Managers TitleAgeSince
Soo-Young Choi CEO
 Chief Executive Officer 63 29/02/20
Byoung Kwon FOU
 Founder 77 26/02/15
Guk-Hee Lee AUD
 Comptroller/Controller/Auditor 76 30/11/16
Members of the board TitleAgeSince
Yong-Sang Cho BRD
 Director/Board Member 76 27/12/18
Byoung Kwon FOU
 Founder 77 26/02/15
Myung-Hee Han BRD
 Director/Board Member 76 27/12/18
More insiders

Quotes

Date Price Change Volume
20/05/24 2,240 -0.88% 73,162
17/05/24 2,260 -0.88% 72,866
16/05/24 2,280 +0.88% 87,887
14/05/24 2,260 +1.12% 74,477

End-of-day quote Korea S.E., May 19, 2024

More quotes

Company Profile

Eutilex Co., Ltd. is a Korea-based company mainly engaged in the production and sale of immunotherapy products. Major products include anticancer T cell therapies and antibody therapies.
Sector
Pharmaceuticals
Calendar
12/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

1st Jan change Capi.
EUTILEX.CO.,LTD Stock Eutilex.Co.,Ltd
-33.73% 61.39M
CSL LIMITED Stock CSL Limited
-2.82% 90.45B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.95% 41.45B
BIOGEN INC. Stock Biogen Inc.
-10.51% 33.57B
UCB Stock UCB
+60.58% 25.73B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-20.09% 14.73B
INCYTE CORPORATION Stock Incyte Corporation
-8.92% 12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.46% 11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.05% 11.44B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.17% 8.79B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A263050 Stock